Avacopan (Tavneos)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses avacopan (Tavneos), 30 mg (3 oral capsules of 10 mg each), twice daily. Indication: For the adjunctive treatment of adult patients with severe antineutrophil cytoplasmic autoantibody–associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard background therapy including glucocorticoids. Avacopan does not eliminate glucocorticoid use.